20/05/2022
Label.BlogRelatedPostsText
STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®
STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®
STADA responds to urgent need by making more medicines
March 2020 saw the highest production output in STADA’s 125-year history as the COVID-19 crisis significantly raised demand for critical medicines.
Corona Survey
Insights into how people in four major European countries are feeling about healthcare issues amid the COVID-19 crises.